The Filing Desk

Assembly Biosciences vs Rockwell Medical

Assembly Biosciences ASMB · Rockwell Medical RMTI · Pharmaceuticals

Assembly Biosciences reported revenue of $72 million in fiscal 2025, about the same as Rockwell Medical's $69 million in fiscal 2025. Assembly Biosciences' revenue grew 153.5% in its latest year, and Rockwell Medical's fell 31.8%. Assembly Biosciences had an operating margin of -16.8%, against -6.8% at Rockwell Medical. Free cash flow was −$41 million at Assembly Biosciences and −$1 million at Rockwell Medical.

Side by side

Assembly BiosciencesRockwell Medical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$72M$69M
Revenue growth153.5%−31.8%
Revenue growth a year, last 5 years−1.8%2.2%
Gross margin—16.9%
Operating margin−16.8%−6.8%
Net margin−8.5%−7.7%
Free cash flow−$41M−$1M
Free cash flow margin−56.9%−1.7%
Return on capital—−17.4%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count86.7%15.8%
Last close$22.50$6.26
P/E at the last close——
Insider trades, last 12 monthssold $14,687sold $3,153
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Assembly BiosciencesRockwell Medical
Operating margin
Percent of revenue
Assembly BiosciencesRockwell Medical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Assembly BiosciencesRockwell Medical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Assembly Biosciences and Rockwell Medical pages.